Active	Status	Sponsor type	Region	Phase	Filter
18 Active 5 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

16 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Harrington, Kevin
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Japan, US, RoW	JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants	Terminated	3	166	Europe, Canada, Japan, US, RoW	Xevinapant (Debio 1143), IMRT, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Head and Neck Cancer	08/24	08/24
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC	Active, not recruiting	2	194	Europe, US, RoW	ISA101b, Cemiplimab, Placebo	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive	09/24	06/25
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors	Active, not recruiting	2	352	Europe, Canada, US	tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin	Seagen Inc., Genmab, Merck Sharp & Dohme LLC	Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck	02/26	11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC	Active, not recruiting	2	65	Europe, US, RoW	ISA101b, Cemiplimab	ISA Pharmaceuticals, Regeneron Pharmaceuticals	Squamous Cell Carcinoma of the Oropharynx	06/24	12/24
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022 Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022	Active, not recruiting	2	95	Europe, US	Pembrolizumab (KEYTRUDA®) and PDS0101	PDS Biotechnology Corp., Merck Sharp & Dohme LLC	Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck	06/25	06/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020 Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020 Initial data from P1 portion of trial in combination with RP1 at SITC 2019 Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019	Recruiting	2	340	Europe, US	RP1, nivolumab, Opdivo	Replimune Inc., Bristol-Myers Squibb	Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC	12/25	12/28
NCT05608876: A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer	Recruiting	2	37	Europe, RoW	Tigilanol Tiglate, EBC-46	QBiotics Group Limited	Head and Neck Cancer	08/25	10/26
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN	Withdrawn	2	130	Europe, US, RoW	RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab	Replimune Inc., Bristol-Myers Squibb	Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	03/26	06/26
NCT05120596: First in Human Study of T3P-Y058-739 (T3P)	Recruiting	1/2	100	Europe	Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)	T3 Pharmaceuticals AG	Advanced Solid Tumor	02/26	10/26
IXACT, NCT06549946: Ixovex-1 Single Agent and Combination Therapy	Recruiting	1/2	18	Europe	Ixovex-1, Pembrolizumab, Keytruda	Psivac Ltd, IQVIA Biotech	Solid Tumor, Head and Neck Cancer	01/27	01/27
Patriot, NCT02223923: Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours	Active, not recruiting	1	87	Europe	AZD6738, Palliative radiotherapy	Royal Marsden NHS Foundation Trust, AstraZeneca, Cancer Research UK, RM/ICR Biomedical Research Centre	Solid Tumour Refractory to Conventional Treatment	12/23	12/23
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours	Active, not recruiting	1	123	Europe, US	RP3, Nivolumab	Replimune Inc., Bristol-Myers Squibb	Advanced Solid Tumor	11/26	11/26
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck	Active, not recruiting	1	36	Europe	NG-641, Pembrolizumab	Akamis Bio	Squamous Cell Carcinoma of the Head and Neck	09/24	10/24
RP2-001-18, NCT04336241: Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Oct 2021 - Dec 2021 : Updated data from trial in combination with RP2 for solid tumors From trial in combination with RP2 for solid tumors at ASCO 2021 Jun 2021 - Jun 2021: From trial in combination with RP2 for solid tumors at ASCO 2021	Recruiting	1	36	Europe	RP2, nivolumab, Opdivo	Replimune Inc.	Cancer	10/26	04/28
Harrington
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022 Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022	Active, not recruiting	2	95	Europe, US	Pembrolizumab (KEYTRUDA®) and PDS0101	PDS Biotechnology Corp., Merck Sharp & Dohme LLC	Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck	06/25	06/25